California Institute for Regenerative Medicine expands therapy access in Northern…
The latest in this situation
How it started
What happened
The California Institute for Regenerative Medicine approved $9 million for Enloe Health in Chico, California, to establish a Community Care Center of Excellence. This center will connect residents in Northern California with FDA-approved cell and gene therapies and clinical trials. The center will initially focus on delivering approved CAR-T therapies and trials for conditions like blood cancers and autoimmune diseases.
From manilatimes.net
Why it matters
The expansion is part of a program launched by the California Institute for Regenerative Medicine to improve access to regenerative medicine therapies for Californians living far from major medical centers. The center will provide clinical trial opportunities, patient support, and workforce training.
From manilatimes.net
Who's involved
- California Institute for Regenerative MedicineApproved $9 million to establish the Community Care Center of Excellence.
- FDAApproves the cell and gene therapies that the new center will deliver.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
The California Institute for Regenerative Medicine might see increased funding and revenue from the successful expansion of its clinical network.
- CRISPR TherapeuticsSpeculative
CRISPR Therapeutics could see increased investment and sales validation due to the expanded market demand for advanced cell and gene therapies.
How it developed
Newest first. Tap a step to see who reported it.- NueCell Bio joined the IRP Program of the California Institute for Regenerative Medicine (CIRM).Sub-event
Network expansion for cell and gene therapies into Northern California sites.1 source
Keep exploring
The entities involved
-
Northern California
region of California, United States
-
California Institute for Regenerative Medicine
research institute in California, United States
Nothing else this week.
- FDA
Related events
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.